Eli Lilly and Company News - February 2026
Eli Lilly Widens Lead in Obesity Market as Wall Street Bets on Oral GLP-1 Pipeline
JPMorgan, Deutsche Bank, and RBC Capital reiterated their confidence in Eli Lilly’s leadership within the expanding obesity treatment market. The investment...
Lilly’s Oral Orforglipron Outperforms Novo’s Semaglutide in Landmark Head-to-Head Trial
Eli Lilly’s experimental once-daily oral drug, orforglipron, demonstrated superior efficacy over Novo Nordisk’s oral semaglutide in a Phase 3 head-to-head...
Eli Lilly Shares Slide as Novo Nordisk Signals 50% Price Cuts for GLP-1 Rivals
Eli Lilly (LLY) shares declined in premarket trading following a pricing announcement from primary rival Novo Nordisk. Novo Nordisk plans to reduce prices for...
Eli Lilly Stock Jumps on Zepbound KwikPen Approval as Rival Novo Nordisk Tumbles 16%
Eli Lilly and Company received U.S. FDA approval for the Zepbound KwikPen, a multi-dose injector for its weight-loss medication. This new device delivers four...
Eli Lilly Shares Surge as Novo Nordisk Weight-Loss Trial Fails
Eli Lilly (LLY) shares surged 4.84% to close at $1058.39 following a clinical setback for competitor Novo Nordisk and the official launch of the Zepbound...
🟢 LLY is trading 3.16% up today after Mounjaro outperforms Novo Nordisk's CagriSema in head-to-head trial
LLY is trading at $1041.44 (+3.16%) after its obesity drug Mounjaro outperformed Novo Nordisk's CagriSema in a head-to-head Phase 3 trial. • The study...
🟢 LLY is trading 3.4% up today on $2.4B Orna Therapeutics acquisition
LLY is trading at $1,094.23 (+3.4%) following Eli Lilly's announcement of a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion. • The...
Eli Lilly Shares Rise on $2.4B Deal to Acquire Circular RNA Pioneer Orna Therapeutics
Eli Lilly signed a definitive agreement to acquire Orna Therapeutics for up to $2.4 billion in cash on February 9, 2026. The transaction includes both upfront...
🟢 LLY is trading 3.6% up today as FDA pledges action against illegal copycat weight-loss drugs
LLY is trading at $1,057.59 (+3.6%) as the FDA pledges swift action against illegal copycat weight-loss drugs, reversing yesterday's sharp 8% decline. • The...
Eli Lilly Debuts Biotech Collaboration Model to Fuel Post-GLP-1 Growth in Gene Editing and Immunology
Eli Lilly and Company launched a new biotech collaboration model to accelerate early-stage drug discovery through external partnerships. This strategic...
Eli Lilly Shares Fall Despite Strong Earnings as Hims & Hers Launches Low-Cost Weight-Loss Pill
Eli Lilly shares fell on Thursday. The decline followed the company's Wednesday report of stronger-than-expected earnings. Lilly also issued a robust financial...
🟢 LLY is trading 9.42% up today after Q4 earnings beat and strong FY2026 guidance
LLY is trading at $1097.95 (+9.42%) following a Q4 2025 earnings beat driven by a 43% surge in revenue to $19.3 billion, fueled by massive demand for Mounjaro...
Eli Lilly's fourth quarter 2025 revenue surged 43% to $19.3 billion, driven by blockbuster sales of Mounjaro and Zepbound.
Eli Lilly reported fourth quarter 2025 revenue of $19.3 billion, a 43% increase year-over-year, driven by strong volume growth. Non-GAAP earnings per share...
Eli Lilly Surges 7% Pre-Market on Tirzepatide Optimism and 31% EPS Growth Forecast
Eli Lilly shares rose 7.18% in pre-market trading on February 4, 2026. The stock reached a price of $1075.49. This follows a close of $1003.46 on February 3....